Effect of vaccination with modified vaccinia ankara (ACAM3000) on subsequent challenge with Dryvax

Journal of Infectious Diseases

Volumn 201, Issue 9, 2010, Pages 1353-1360

  Seaman, Michael S ^a,e   Wilck, Marissa B ^b,e   Baden, Lindsey R ^b,e   Walsh, Stephen R ^c,e   Grandpre, Lauren E ^a   Devoy, Colleen ^a   Giri, Ayush ^a   Noble, Lizanne C ^b   Kleinjan, Jane A ^b   Stevenson, Kristen E ^d   Kim, Haesook T ^d   Dolin, Raphael ^a,b,e  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACAM 3000; MODIFIED VACCINIA ANKARA; PLACEBO; SMALLPOX VACCINE; UNCLASSIFIED DRUG; VACCINIA VACCINE; DRYVAX VACCINE; LIVE VACCINE; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HUMAN EXPERIMENT; HUMORAL IMMUNITY; IMMUNIZATION; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; TISSUE CULTURE; VACCINATION; ADULT; DOSE RESPONSE; FEMALE; IMMUNOLOGY; INTRADERMAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; TIME; VACCINIA VIRUS; VIRUS SHEDDING;

ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HUMANS; INJECTIONS, INTRADERMAL; INJECTIONS, INTRAMUSCULAR; MALE; SMALLPOX VACCINE; TIME FACTORS; VACCINATION; VACCINES, ATTENUATED; VACCINIA VIRUS; VIRUS SHEDDING; YOUNG ADULT;

EID: 77950951092     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/651560     Document Type: Article

References (32)

1. Fenner F, Henderson D, Arita I, Jezek Z. Smallpox and its eradication. Geneva, Switzerland: World Health Organization, 1988:307.
2. Wilck MB, Seaman MS, Baden LR, et al. Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration. J Infect Dis 2010;201(9):1361-1370 (in this issue).
3. McCurdy LH, Larkin BD, Martin JE, Graham BS. Modified vaccinia Ankara: potential as an alternative smallpox vaccine. Clin Infect Dis 2004;38:1749-1753.
4. Halsell JS, Riddle JR, Atwood JE, et al. Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel. JAMA 2003; 289:3283-3289.
5. Eckart RE, Love SS, Atwood JE, et al Incidence and follow-up of inflammatory cardiac complications after smallpox vaccination. J Am Coll Cardiol 2004;44:201-205.
6. Cassimatis DC, Atwood JE, Engler RM, Linz PE, Grabenstein JD, Vernalis MN. Smallpox vaccination and myopericarditis: a clinical review, J Am Coll Cardiol 2004;43:1503-1510.
7. Neff'J, Modlin. J, Birkhead GS, et al. Monitoring the safety of a smallpox vaccination program in the United States: report of the joint Smallpox Vaccine Safety Working Group of the Advisory Committee on Immunization Practices and the Armed Forces Epidemiological Board, Clin Infect Dis 2008;46(Suppl 3):S258-S270.
8. Fulginiti VA, Papier A, Lane JM, Neff JM, Henderson DA. Smallpox vaccination: a review, part. I. Background, vaccination technique, normal vaccination and revaccination, and expected normal reactions. Clin Infect Dis 2003;37:241-250.
9. Centers for Disease Control and Prevention. Evaluation of takes and non-takes, http://www.bt.cdc.gov/agent/smallpox/vaccination/takes-non -takes.asp. Accessed 22 July 2009.
10. Parrino J, McCurdy LH, Larkin BD, et al. Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naive and vaccinia-immune individuals. Vaccine 2007; 25: 1513-1525.
11. Cleveland WS. Robust locally weighted regression and smoothing acatterplots. J Am Stat Assoc 1979; 74:829-830.
12. Fan J. Design-adaptive nonparametric regression. J Am Stat Assoc 1992;87:998-1004.
13. Frey SE, Newman FK, Kennedy JS, et al. Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge. Vaccine 2007; 25:8502-8573.
14. Earl PL, Americo JL, Wyutt LS, et al. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature 2004;428:182-185.
15. Nigam P, Earl PL, Americo JL, et al. DNA/MVA HIV-1/AIDS vaccine elicits long-lived vaccinia virus-specific immunity and confers protection against a lethal monkeypox challenge. Virology 2007; 366:73-83.
16. Kaufman DR, Goudsmit J, Holterman L, et al, Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice. J Virol 2008; 82:6829-6837.
17. Heraud JM, Edghill-Smith Y, Ayala V, et al. Subunit recombinant vaccine protects against monkeypox. J Immunol 2006;177:2552-2564. (Pubitemid 44201014)
18. Hooper JW, Thompson E, Wilhelmsen C, et al. Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox, J Virol 2004; 78: 4433-4443. (Pubitemid 38501063)
19. Berhanu A, Wilson RL, Kirkwood-Watts DL, et al, Vaccination of BALB/ c mice with Escherichia coli'-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge. J Virol 2008;82:3517-3529.
20. Lustig S, Fogg C, Whitbeck JC, Eisenberg RJ, Cohen GH, Moss B, Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge. J Virol 2005;79:13454-13462. 21. Czerny CP, Mahnel H, Structural and functional analysis of orthopoxvirus epitopes with neutralizing monoclonal antibodies J Gen Virol 1990; 71 (Pt 10):2341-2352. (Pubitemid 41508158)
21. Galmiche MC, Goenaga J, Wittek R, Rindisbacher L, Neutralizing and protective antibodies directed against vaccinia virus envelope antigens, Virology 1999;254:71-80. (Pubitemid 29391715)
22. Ramirez JC, Tapia E, Esteban M, Administration to mice of a monoclonal antibody that neutralizes the intracellular mature virus form of vaccinia virus limits virus replication efficiently under prophylactic and therapeutic conditions. J Gen Virol 2002;83:1059-1067. (Pubitemid 34477278)
23. Mack TM, Noble J Jr, Thomas DB, A prospective study of serum antibody and protection against smallpox Am J Trop Med Hyg 1972;21:214-218.
24. Sarkar JK, Mitra AC, Mukherjee MK. The minimum protective level of antibodies in smallpox. Bull World Health Organ 1975;52:307-311.
25. Downie AW, McCarthy K. The antibody response in man following infection with viruses of the pox group. III. Antibody response in smallpox. J Hyg (Lond) 1958;56:479-487.
26. Edghill-Smith Y, Golding H, Manischewitz J, et al, Smallpox vaccineinduced antibodies are necessary and sufficient for protection against monkeypox virus, Nat Med 2005; 11:740-747. (Pubitemid 41021206)
27. Hammarlund E, Lewis MW, Hansen SG, et al. Duration of antiviral immunity after smallpox vaccination. Nat Med 2003;9:1131-11117 (Pubitemid 37173696)
28. Kempe CH, Studies on smallpox and complications of smallpox vaccination. Pediatrics 1960;26:176-189.
29. Zinkernagel RM, Althage A. Antiviral protection by virus-immune cytotoxic T cells: infected target cells are lysed before infectious virus progeny is assembled. J Exp Med 1977;145:644-651. (Pubitemid 8049616)
30. Derby M, Alexander-Miller M, Tse R, Berzofsky J. High-avidity CTL exploit two complementary mechanisms to provide better protection against viral infection than low-avidity CTL. J Immunol 2001; 166:1690-1697. (Pubitemid 32114651)
31. McCurdy LH, Rutigliano JA, Johnson TR, Chen M, Graham BS, Modified vaccinia virus Ankara immunization protects against lethal challenge with recombinant vaccinia virus expressing murine interleukin,-4. J Virol 2004;78:12471-12479. (Pubitemid 39458765)
32. Belyakov IM, Earl P, Dzutsev A, et al. Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc Natl Acad Sci U S A 2003;100:9458-9463. (Pubitemid 37033950)